Mayo Clinic Proceedings Home
MCP Digital Health Home

PSA Doubling Time as a Predictor of Clinical Progression After Biochemical Failure Following Radical Prostatectomy for Prostate Cancer


      To characterize the clinical progression of disease in men who have undergone prostatectomy for clinically localized prostate cancer and have postoperative biochemical failure (elevated prostate-specific antigen [PSA] level) and to identify predictors of clinical disease progression, including the possible effect of PSA doubling time (PSADT).

      Patients and Methods

      Between 1987 and 1993, 2809 patients underwent radical retropubic prostatectomy for clinically localized (≤T2) disease. In our database, all patients with postoperative biochemical failure (PSA level ≥0.4 ng/mL) were identified. The PSADT was estimated using log linear regression on all PSA values (excluding those values determined after administration of hormonal therapy) within 15 months after biochemical failure. All patients had regular PSA measurements from the time of surgery through the follow-up period. Systemic progression (SP) was defined as evidence of metastatic disease on a bone scan. Local recurrence (LR) was defined on the basis of digital rectal examination, transrectal ultrasonography, and biopsy. The SP-free survival and LR/SP-free survival (survival free of both LR and SP) after biochemical failure was estimated with use of the Kaplan-Meier method. Patients with prostate cancer treatment after biochemical failure had their follow-up censored from this study at the time of treatment.


      Postoperative biochemical failure occurred in 879 men (31%). The mean follow-up from time of biochemical failure was 4.7 years (range, 0.5–11 years). The mean time to biochemical failure was 2.9 years (median, 2.4 years). The overall mean SP-free survival from time of biochemical failure was 94% and 91% at 5 and 10 years, respectively. The mean LR/SP-free survival was 64% and 53% at 5 and 10 years, respectively. By using univariate analysis on the 587 patients with PSADT data, significant risk factors for SP were PSADT (P<.001) and pathologic Gleason score (P=.005); for LR/SP, significant risk factors included PSADT (P<.001) and pathologic Gleason score (P<.001). In multivariate Cox models analysis, only PSADT remained a significant risk factor for both SP and LR/SP (P<.001). Mean 5-year SP-free survival was 99%, 95%, 93%, and 64% for patients with PSADT of 10 years or longer, 1.0 to 9.9 years, 0.5 to 0.9 year, and less than 0.5 year, respectively; the respective mean LR/SP-free survivals were 87%, 62%, 46%, and 38%. The percentage of patients with PSADT of less than 0.5 year was considerably higher if the type of first clinical event was SP (48%) compared with LR (18%) (P<.001).


      For patients who have undergone radical prostatectomy, a rising PSA level suggests evidence of residual or recurrent prostate cancer. Many men remain free of clinical disease for an extended time after biochemical failure following radical prostatectomy for clinically localized prostate cancer. The PSADT appears to be an important predictor of SP and also of any clinical progression (local or systemic). These data may be useful when counseling men regarding the timing of adjuvant therapies.
      LR (local recurrence), PSA (prostate-specific antigen), PSADT (prostate-specific antigen doubling time), RRP (radical retropubic prostatectomy), SP (systemic progression)
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Mayo Clinic Proceedings
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Amling CL
        • Bergstralh EJ
        • Blute ML
        • Slezak JM
        • Zincke H
        Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point?.
        J Urol. 2001; 165: 1146-1151
        • Zincke H
        • Oesterling JE
        • Blute ML
        • Bergstralh EJ
        • Myers RP
        • Barrett DM
        Long-term (15 years) results after radical prostatectomy for clinically localized (stage T2c or lower) prostate cancer.
        J Urol. 1994; 152: 1850-1857
        • Pound CR
        • Partin AW
        • Epstein JI
        • Walsh PC
        Prostate-specific antigen after anatomic radical retropubic prostatectomy: patterns of recurrence and cancer control.
        Urol Clin North Am. 1997; 24: 395-406
        • Trapasso JG
        • DeKernion JB
        • Smith RB
        • Dorey F
        The incidence and significance of detectable levels of serum prostate specific antigen after radical prostatectomy.
        J Urol. 1994; 152: 1821-1825
        • Dillioglugil O
        • Leibman BD
        • Kattan MW
        • Seale-Hawkins C
        • Wheeler TM
        • Scardino PT
        Hazard rates for progression after radical prostatectomy for clinically localized prostate cancer.
        Urology. 1997; 50: 93-97
        • Catalona WJ
        • Smith DS
        Cancer recurrence and survival rates after anatomic radical retropubic prostatectomy for prostate cancer: intermediate-term results.
        J Urol. 1998; 160: 2428-2438
        • Amling CL
        • Blute ML
        • Bergstralh EJ
        • Seay TM
        • Slezak J
        • Zincke H
        Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years.
        J Urol. 2000; 164: 101-105
        • Pound CR
        • Partin AW
        • Eisenberger MA
        • Chan DW
        • Pearson JD
        • Walsh PC
        Natural history of progression after PSA elevation following radical prostatectomy.
        JAMA. 1999; 281: 1591-1597
        • Patel A
        • Dorey F
        • Franklin J
        • deKernion JB
        Recurrence patterns after radical retropubic prostatectomy: clinical usefulness of prostate specific antigen doubling times and log slope prostate specific antigen.
        J Urol. 1997; 158: 1441-1445
        • Pruthi RS
        • Johnstone I
        • Tu IP
        • Stamey TA
        Prostate-specific antigen doubling times in patients who have failed radical prostatectomy: correlation with histologic characteristics of the primary cancer.
        Urology. 1997; 49: 737-742
        • Zincke H
        • Blute ML
        • Fallen MJ
        • Farrow GM
        Radical prostatectomy for stage A adenocarcinoma of the prostate: staging errors and their implications for treatment recommendations and disease outcome.
        J Urol. 1991; 146: 1053-1058
        • Gleason DF
        • Veterans Administration Cooperative Urological Research Group
        Histologic grading and clinical staging of prostatic carcinoma.
        in: Tannenbaum M Urologic Pathology: The Prostate. Lea & Febiger, Philadelphia, Pa1977: 171-187
        • Sobin LH
        • Wittekind CH
        TNM Classification of Malignant Tumours. John Wiley & Sons, Inc, New York, NY1997: 170-173
        • Lange PH
        • Ercole CJ
        • Lightner DJ
        • Fraley EE
        • Vessella R
        The value of serum prostate specific antigen determinations before and after radical prostatectomy.
        J Urol. 1989; 141: 873-879
        • Anscher MS
        Prostate bed massage as a means to determine the source of a rising prostate specific antigen after radical prostatectomy.
        Am J Clin Oncol. 1995; 18: 481-483
        • Malavaud B
        • Salama G
        • Miedouge M
        • et al.
        Influence of digital rectal massage on urinary prostate-specific antigen: interest for the detection of local recurrence after radical prostatectomy.
        Prostate. 1998; 34: 23-28
        • Iwakiri J
        • Grandbois K
        • Wehner N
        • Graves HC
        • Stamey T
        An analysis of urinary prostate specific antigen before and after radical prostatectomy: evidence for secretion of prostate specific antigen by the periurethral glands.
        J Urol. 1993; 149: 783-786
        • Wojno KJ
        • Vashi AR
        • Schellhammer PF
        • Wright Jr, GL
        • Montie JE
        Percent of free prostate-specific antigen values in men with recurrent prostate cancer after radical prostatectomy.
        Urology. 1998; 52: 474-478

      Linked Article

      • The Utility of PSA Doubling Time to Monitor Prostate Cancer Recurrence
        Mayo Clinic ProceedingsVol. 76Issue 6
        • Preview
          One of the most challenging issues in prostate cancer diagnosis and treatment is the determination of which patients have clinically important tumors. This issue is relevant not only in men with newly diagnosed tumors, but also in men whose disease recurs after primary treatment for prostate cancer. Specifically, it is important to segregate patients with “low-risk” cancers that can be observed from patients with “high-risk” cancers that may benefit from early treatment. To stratify patients by risk, researchers have used tumor grade, tumor stage, prostate-specific antigen (PSA) level, and radiographic studies such as endorectal magnetic resonance imaging, immunoscintigraphic scanning, and positron emission tomography.
        • Full-Text
        • PDF